All In Biotech

Drug Trial Radar · NCT04031742

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Phase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia.

Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18

Actual

Start

Sep 29, 2019

Primary completion

Dec 30, 2021

Study completion Dec 30, 2021

Sponsor

Sponsor type
Industry
First posted
Jul 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial hypercholesterolemia.

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

  • IBI306Biological

    Administered by subcutaneous injection

  • IBI306Biological

    Administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C).Time frame: Baseline and Week 12
  2. Part 2: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline and Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.